Silexion Therapeutics Corp (NASDAQ:SLXN) Stock Short Interest Report for October

Silexion Therapeutics Corp (NASDAQ:SLXN – Get Free Report) was the recipient of a significant decline in short interest in October. As of October 30th, there was short interest totaling 82,127 shares, a decline of 49.5% from the October 15th total of 162,704 shares. Based on an average daily trading volume, of 1,493,800 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.5% of the shares of the stock are short sold.

Silexion Therapeutics Stock Down 4.0%

NASDAQ SLXN traded down $0.08 during mid-day trading on Monday, hitting $1.90. The stock had a trading volume of 10,054 shares, compared to its average volume of 134,841. Silexion Therapeutics has a 52-week low of $1.82 and a 52-week high of $777.12. The company has a market cap of $440,800.00, a price-to-earnings ratio of -0.04 and a beta of -0.30. The company has a 50 day simple moving average of $5.70 and a 200 day simple moving average of $140.28.

Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($13.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($218.40) by $204.70. As a group, equities analysts anticipate that Silexion Therapeutics will post -112.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on SLXN. Wall Street Zen upgraded Silexion Therapeutics to a “hold” rating in a research report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Friday, September 11th. Finally, Maxim Group lowered shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold”.

Check Out Our Latest Stock Analysis on Silexion Therapeutics

About Silexion Therapeutics

(Get Free Report)

Silexion Therapeutics Ltd. (NASDAQ: SLXN) is an Israel-based clinical-stage biotechnology company developing RNA-based medicines for the treatment of solid tumors driven by mutations in the KRAS oncogene. The company’s technology is designed to selectively silence cancer-causing KRAS mutations while limiting exposure to healthy tissue. Silexion’s lead program, siG12D-LODER, is an investigational RNA interference therapy targeting the KRAS G12D mutation, which is frequently found in pancreatic and other difficult-to-treat cancers.

See Also

Receive News & Ratings for Silexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.